# US 2025/0164466 A1 · Method for producing tissue constructs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0164466 A1
- Document ID: US20250164466A1
- Status: Published application
- Kind: A1
- Application number: 18/840,390
- Filed: 2023-02-16
- Published: 2025-05-22
- Earliest claimed: 2022-02-22
- Assignees: MimiX Biotherapeutics SA
- Applicants: MimiX Biotherapeutics SA
- Inventors: Dobrila Nesic; Nicola Di Marzio; Marc Thurner; Tiziano Serra
- Web page: https://patentgrep.com/patent/US20250164466A1

## CPC

- A61L 27/362: {Skin, e.g. dermal papillae}
- G01N 33/5082: {Supracellular entities, e.g. tissue, organisms}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61L 27/3695: {characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this (A61L27/3687, A61L27/3691 take precedence)}
- A61L 27/44: having a macromolecular matrix
- A61L 27/60: Materials for use in artificial skin
- C12N 5/0625: {Epidermal cells, skin cells; Cells of the oral mucosa}
- C12N 5/0698: {Skin equivalents}
- C12N 13/00: Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- A61L 2430/40: Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
- C12N 2502/11: blood or immune system cells
- C12N 2521/10: Sound, e.g. ultrasounds
- C12N 2533/40: Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- G01N 2800/245: Transplantation related diseases, e.g. graft versus host disease
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention concerns a method for producing a tissue construct comprising microtissues suspended or resuspended in a volume of a blood sample, such as a whole blood sample or a processed blood sample, and exposing the suspension to a static acoustic wave field causing aggregates of microtissues to arrange in patterns defined by the waves. The tissue constructs are layers of coagulated blood containing the patterned microtissues which may be used for a variety of purposes, including for tissue grafting or for diagnostic purposes. The constructs may also be layered to compose more complex tissue structures.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method for producing a human or animal tissue construct, comprising
providing a tissue sample or a plurality of microtissues,
providing a volume of a liquid sample for suspending the tissue sample,
suspending or resuspending the tissue sample or the microtissues in said volume of liquid sample in a receptacle,
exposing the receptacle containing the tissue sample or the microtissues suspended in the liquid sample to a static acoustic wave field to cause aggregates of cells comprised in the tissue sample, or aggregates of the microtissues to arrange in a pattern defined by the static acoustic waves,
wherein
the liquid sample is a blood sample, such as a whole blood sample or a processed blood sample, wherein said processed blood sample comprises or is supplemented with coagulation promoting components for causing coagulation of the liquid sample, and
in that the method comprises the step of coagulation of the blood sample to form a coagulated blood layer providing a scaffold for free migration of the aggregates, such as to create a patterned blood tissue construct.

### Claim 18 (depends on 17)

The method of claim 17, further comprising an incubation step at temperatures ranging from 20° C. to 40° C., ideally at 35° C. to 38° C. for ex vivo or in vitro to facilitate cell growth and/or maturation of the patterned blood tissue construct.

### Claim 19 (depends on 17)

The method of claim 17, wherein the acoustic wave field has a frequency of 10 Hz to 600 Hz, preferably of 30 Hz to 200 Hz, or of 50 Hz to 100 Hz.

### Claim 20 (depends on 17)

The method of claim 17, wherein exposure time to fields ranges from 1 min to 20 mins, preferably from 2 mins to 10 mins.

### Claim 21 (depends on 17)

The method of claim 17, wherein the microtissues are organoids, spheroids, or combinations thereof.

### Claim 22 (depends on 17)

The method of claim 17, wherein the microtissues are micrografts.

### Claim 23 (depends on 22)

The method of claim 22, wherein the micrografts have a maximum transversal dimension of no more than 1000 μm, or no more than 500 μm, or of no more than 100 μm, or 80 μm±20 μm.

### Claim 24 (depends on 17)

The method of claim 17, wherein the tissue sample is a suspension of cells, or a suspension of concentrated cells.

### Claim 25 (depends on 24)

The method of claim 24, wherein the cells are derived from adipose tissue, from lymphatic tissue, from bone marrow, or from blood.

### Claim 26 (depends on 17)

The method of claim 17, wherein multiple iterations of the method are performed to generate a series of patterned blood tissue construct which are subsequently superposed as layers.

### Claim 27 (depends on 26)

The method of claim 26, wherein one or more layers each comprises different types of tissue samples or microtissues.

### Claim 28 (depends on 26)

The method of claim 26, wherein two or more layers differ from each other in the type of tissue sample and/or microtissue comprised in said layers.

### Claim 29 (depends on 17)

The method of claim 17 for generating a tissue graft, further comprising transferring the patterned blood tissue construct onto a non-woven support structure, for example onto a silicon support sheet.

### Claim 30 (depends on 29)

The method of claim 29, wherein the tissue graft is a skin tissue graft.

### Claim 31 (depends on 17)

Use of a tissue construct produced according to claim 17 for in vitro or ex vivo diagnostic purposes.

### Claim 32 (depends on 30)

Use of a tissue construct produced according to claim 30 for in vitro or ex vivo diagnostic purposes.

### Claim 33 (depends on 17)

A method of diagnosis performed on a tissue construct produced according to claim 17, comprising the steps of
exposing the tissue construct to a reagent for identifying a biological unit, a biomarker, or an analyte of interest,
detecting the presence, absence, or the level of said biological unit, biomarker, or analyte in tissue construct, and
comparing the obtained detection result to the expected presence, absence, or level of said biological unit, biomarker or analyte in healthy tissue.

### Claim 34 (depends on 33)

The method of claim 33, further comprising diagnosing a disease or a status of a disease based on the comparison step.

### Claim 35 (depends on 17)

A bank of biological tissue grafts produced according to claim 17.
